Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health field, with key products including various types of sleep breathing machines and monitoring devices [2] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents across multiple countries [2] Financial Performance - For the first quarter of 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, up 44.11% year-on-year, with a gross profit margin of 49.57% [2] Market Position - As of August 12, the company's stock closed at 97.77 yuan, up 6.63%, with a rolling price-to-earnings (PE) ratio of 49.38, marking a new low in 341 days, and a total market capitalization of 8.76 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 57.51, with a median of 41.25, placing Ruimait at the 84th position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders for Ruimait reached 9,118, an increase of 1,481 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

证券代码：301367 证券简称：瑞迈特 公告编号：2025-046 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份触及1%整数倍的公告 公司持股5%以上股东珠海合晅投资中心（有限合伙）及其一致行动人上海 盛旻创业投资合伙企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 北京瑞迈特医疗科技股份有限公司（以下简称"公司"）于近日收到珠海合 晅投资中心（有限合伙）（以下简称"合晅投资"）及其一致行动人上海盛旻创 业投资合伙企业（有限合伙）（以下简称"盛旻创投"）和南京合灏创业投资企 业（有限合伙）（以下简称"南京合灏"）出具的《关于减持公司股份触及 1% 整数倍的告知函》。公司于 2025 年 6 月 19 日披露了《关于持股 5%以上股东及 其一致行动人减持股份的预披露公告》（公告编号：2025-044），于 2025 年 8 月 1 日披露了《关于持股 5%以上股东及其一致行动人减持股份触及 1%整数倍的公 告》（公告编号：20 ...

瑞迈特（301367.SZ）8月12日在投资者互动平台表示，上市公司股东人数属于应当在定期报告中披露的 信息。为确保信息披露的公平性及合规性，公司在非定期报告时点原则上不单独披露股东人数变动信 息，最新股东人数数据请以公司在中国证监会指定信息披露媒体发布的定期报告为准。公司2025年半年 度报告预计于2025年8月28日披露，其中将包含截至2025年6月末的股东人数信息，您可届时关注。 每经AI快讯，有投资者在投资者互动平台提问：请问最新三期的股东户数各是多少？ （文章来源：每日经济新闻） ...

截至2025年8月8日收盘，瑞迈特股价报92.21元，较前一交易日上涨5.53元，涨幅6.38%。当日成交量为 30627手，成交金额达2.76亿元。 瑞迈特所属医疗器械板块，公司主营业务为医疗健康领域相关产品的研发、生产和销售。公司产品涵盖 多个医疗细分领域，在北京地区具有业务布局。 8月8日，瑞迈特发生一笔大宗交易，机构专用账户通过大宗交易方式买入20万股，成交金额1829.8万 元，成交价91.49元，较当日收盘价折价0.78%。该笔交易占当日成交金额的6.63%。 资金流向方面，8月8日主力资金净流入313.65万元，占流通市值的0.06%。近五个交易日主力资金累计 净流出1674.61万元，占流通市值的0.32%。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有37家上市医疗设备公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁的董秘是市场的中坚力量，占比共计达到44%；50岁以上的董秘占 比为25%；40岁及以下董秘群体占比为31%。其中，目前仍任职的最年轻的男上市公司董秘年龄36岁， 为康众医疗的尹晟；最年轻的女董秘年龄为32岁，为鱼跃医疗的王瑞洁。 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 从薪酬变动幅度看，港通医疗的陈兴根2024年薪酬降幅最大，同比降幅达28.17%；瑞迈特的杜祎程薪 酬增幅最大，同比涨幅达87.43%。 责任编辑：公司观察 其中，年薪排行前五的董秘分别为迈瑞医疗的李文楣、联影医疗的TAO CAI、理邦仪器的祖幼冬、华大 智造的韦炜、鱼跃医疗的王瑞洁，五人年薪分别为738.76万元、165.11万元、16 ...

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health field [1] - The main products include various types of sleep breathing machines, masks, and monitoring devices [1] - The company holds a total of 633 domestic patents, including 107 invention patents and 390 utility model patents, as well as 202 international patents [1] Financial Performance - For Q1 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11% [2] - The net profit for the same period was 71.93 million yuan, showing a year-on-year growth of 44.11% [2] - The gross profit margin stood at 49.57% [2] Market Position - As of August 6, the company's stock closed at 87.34 yuan, with a rolling price-to-earnings (PE) ratio of 44.11 times [1] - The average PE ratio in the medical device industry is 53.93 times, with a median of 37.81 times, placing Ruimait at the 83rd position in the industry ranking [1][2] - The total market capitalization of the company is 7.826 billion yuan [1]

Core Insights - The company, Ruimait, closed at 88.87 yuan on August 5, with a 1.55% increase, resulting in a rolling PE ratio of 44.89 times and a total market value of 7.963 billion yuan [1] - In the medical device industry, the average PE ratio is 54.24 times, with a median of 37.92 times, placing Ruimait at the 83rd position in the industry ranking [1] - The company experienced a net inflow of 6.937 million yuan in principal funds on August 5, although it has seen a total outflow of 28.488 million yuan over the past five days [1] Company Overview - Ruimait specializes in manufacturing medical devices and consumables in the field of respiratory health, with key products including various types of sleep breathing machines and monitoring devices [1] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, along with 202 international patents [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 265 million yuan, reflecting a year-on-year increase of 38.11%, and a net profit of 71.9314 million yuan, up 44.11% year-on-year, with a gross profit margin of 49.57% [2] - The company's PE (TTM) is 44.89, while the industry average is 54.24, and the industry median is 37.92 [2]

Core Viewpoint - The stock price of Ruimait has increased by 1.71 yuan to 87.51 yuan, indicating positive market sentiment [1] Group 1: Stock Performance - The opening price was 85.36 yuan, with an intraday high of 87.65 yuan and a low of 84.85 yuan [1] - The trading volume reached 9,623 hands, with a total transaction amount of 0.83 billion yuan [1] - The company's total market capitalization is 7.841 billion yuan, while the circulating market capitalization is 4.946 billion yuan [1] Group 2: Fund Flow - On August 4, the net outflow of main funds was 6.028 million yuan, accounting for 0.12% of the circulating market capitalization [1] - Over the past five trading days, the cumulative net outflow reached 33.1115 million yuan, representing 0.67% of the circulating market capitalization [1]

证券代码：301367 证券简称：瑞迈特 公告编号：2025-045 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份触及1%整数倍的公告 公司持股5%以上股东珠海合晅投资中心（有限合伙）及其一致行动人上海 盛旻创业投资合伙企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 2 | 京 | 其中：无限售条件股 | 35.8589 | 0.40 | 25.5189 | 0.28 | 合 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 份 | 灏 | 有限售条件股份 | | | | | | | | 0 | 0.00 | 0 | 0.00 | | | | | | | 持有股份 | 1,688.7790 | 18.85 | 1,604.7090 | 17.91 | | | | | | 合 | 其中：无限售条件股 | 1,688.7790 | 18.85 | 1,604.7090 | 17.91 | 计 | 份 | | | 有限售 ...

Group 1 - The core business of the company is the manufacturing of medical devices and consumables in the respiratory health field, including various types of sleep breathing machines and monitoring devices [2] - As of March 31, 2025, the company had 9,118 shareholders, an increase of 1,481 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 265 million yuan, a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, a year-on-year increase of 44.11%, with a gross profit margin of 49.57% [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 43.53, while the industry average PE ratio is 55.15, and the industry median is 37.48, placing the company at the 81st position in the industry ranking [1][3] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents [2]